Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

Published Date: 23 Jun 2026

At 4 years, dostarlimab plus chemotherapy reduced the risk for death by two thirds among patients with dMMR/MSI-H advanced endometrial cancer, pointing to curative potential, experts say.

Read Full News

Latest News

Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

New Immune Therapy Boosts Disease Control in Prostate Cancer

An adenoviral-based immunotherapy improved disease-free survival in men with localized intermediate- or high-risk disease, but experts had reservations.

e-Cigarettes and Lung Cancer: Is Harm Reduction Overstated?

A large study links the use of e-cigarettes after smoking cessation to higher lung cancer incidence and mortality than complete nicotine abstinence.

Multiple Myeloma Patients Have Unequal Access to Treatment

Lack of access to innovative and effective treatments compromises survival outcomes for many patients in Europe with multiple myeloma.

Is There a Role for Stimulants in Beating Cancer Fatigue?

Guidelines on treating cancer fatigue offer little enthusiasm for methylphenidate and other stimulants. But a recent meta-analysis suggests the medications deserve a rethink.

Combination Treatment May Improve Multiple Myeloma Outcomes

Post hoc analysis of the MajesTEC-3 trial shows the efficacy of the teclistamab plus daratumumab combination in hard-to-treat patients with high cytogenetic and functional risk.

Todays Updates

High Blood Pressure? Consider the Aldosterone Connection

Less than 1% of patients with primary aldosteronism are diagnosed. The Curbsiders are here to help change that with practical screening and treatment tips.

Diagnosing Alpha-Gal Syndrome in Children

Dr. Hodge emphasizes that carefully taking a history is the first step toward diagnosing this relatively rare syndrome in children.

Ginkgo biloba Adds an Edge in Pediatric Enuresis

Ginkgo biloba extract, alone or in combination with desmopressin, is safe and effective for treating monosymptomatic nocturnal enuresis in children, a trial shows.

Workplace Bending May Triple Miscarriage Risk

Frequently bending forward ≥ 30° in an occupation was associated with an increased risk of miscarriage.

Nitrous Oxide Cuts Pain in Office Hysteroscopy

Inhaled nitrous oxide significantly reduces pain during office hysteroscopy compared with ambient air.

What 300,000 Implants Say About Light Adjustable Lens

An intraocular lens that can be adjusted after cataract surgery has better outcomes for meeting target vision than other lenses, but patient selection and involvement are key.

Parkinson’s Disease Deaths Decline Among Older US Adults

Death rates from Parkinson’s disease among US older adults decline in 2024 following a steady rise from 2014 to 2021, new data show.

Todays Updates

High Blood Pressure? Consider the Aldosterone Connection

Less than 1% of patients with primary aldosteronism are diagnosed. The Curbsiders are here to help change that with practical screening and treatment tips.

Diagnosing Alpha-Gal Syndrome in Children

Dr. Hodge emphasizes that carefully taking a history is the first step toward diagnosing this relatively rare syndrome in children.

Ginkgo biloba Adds an Edge in Pediatric Enuresis

Ginkgo biloba extract, alone or in combination with desmopressin, is safe and effective for treating monosymptomatic nocturnal enuresis in children, a trial shows.

Workplace Bending May Triple Miscarriage Risk

Frequently bending forward ≥ 30° in an occupation was associated with an increased risk of miscarriage.

Nitrous Oxide Cuts Pain in Office Hysteroscopy

Inhaled nitrous oxide significantly reduces pain during office hysteroscopy compared with ambient air.

What 300,000 Implants Say About Light Adjustable Lens

An intraocular lens that can be adjusted after cataract surgery has better outcomes for meeting target vision than other lenses, but patient selection and involvement are key.

Parkinson’s Disease Deaths Decline Among Older US Adults

Death rates from Parkinson’s disease among US older adults decline in 2024 following a steady rise from 2014 to 2021, new data show.

Latest News

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

An adenoviral-based immunotherapy improved disease-free survival in men with localized intermediate- or high-risk disease, but experts had reservations.

A large study links the use of e-cigarettes after smoking cessation to higher lung cancer incidence and mortality than complete nicotine abstinence.

Lack of access to innovative and effective treatments compromises survival outcomes for many patients in Europe with multiple myeloma.

Guidelines on treating cancer fatigue offer little enthusiasm for methylphenidate and other stimulants. But a recent meta-analysis suggests the medications deserve a rethink.

Post hoc analysis of the MajesTEC-3 trial shows the efficacy of the teclistamab plus daratumumab combination in hard-to-treat patients with high cytogenetic and functional risk.

News All Time

Smartphone App Detects Eye Cancers From Photos

A smartphone app that analyzes images of the eye may enable early screening for cancers of the eye surface, flag lesions at high risk for specialist review, and expand access beyond clinics.

Isatuximab Boosts MRD Negativity in Multiple Myeloma

Researchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.

Novel ADC Improves Survival in Metastatic TNBC

Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.

Fuzuloparib Add-On Improves Metastatic Prostate Cancer rPFS

Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.

Chiauranib Slows Platinum-Resistant Ovarian Cancer

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

Snus Linked to Gingival Damage, Raising Safety Questions

Research shows that snus and newer oral nicotine pouches are associated with localized soft tissue changes, prompting greater attention to their oral health effects.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Therapy Combo Improves Radiographic PFS in Prostate Cancer

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Abemaciclib Slows Progression of Advanced Liposarcoma

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

Teclistamab Alone Ups Previously Treated Myeloma Survival

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

Trial Supports Ivonescimab and Chemo for NSCLC Survival

A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.

Asandeutertinib Tops Osimertinib for NSCLC With Brain Mets

In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.

FDA Approves Novel Targeted Therapy for Rare Blood Cancer

The CD123-directed antibody and alkylating agent conjugate led to complete remission or clinical complete remission in nearly 70% of treatment-naive patients in a single arm study.

Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer

The combination therapy is approved for BCG-naive patients with high-risk non-muscle-invasive disease.

Can Fasting Around Chemo Improve Ovarian Cancer Outcomes?

Women with ovarian cancer who fast shortly before and after chemotherapy have lower insulin levels, stronger tumor responses, and longer progression-free survival in a small randomized trial.

Recommended News For You

Low-Dose Radiation Provides Almost Perfect Control Over Slow-Growing Lymphoma.

Colorectal Cancer Screening Uptake Tripled in 45-49 Age Group

Make the Diagnosis: Can You Explain Her Rash and Conjunctival Injection?

A consensus statement from researchers on the proper use of Lu-177 PSMA-617 radionuclide therapy and patient selection is published.

Low Income, Education Tied to Depression in Older Adults

Never in a million years did I think I'd have to limit my chemotherapy.

Paging Dr. AI; Myth Busting in Cancer; Oncologists Shine in Malpractice Survey

Recommended Articles For You

How Cancer Cells Evade Immune Destruction and the Fight Back 

The New Frontier of Cancer Survivorship: Navigating the Long-Term Effects of Immunotherapy and Targeted Therapies 

Therapeutic Innovations Through Germline Predisposition in Acute Leukemias and Myeloid Neoplasms 

Optimizing Platelet Transfusions: Balancing Benefits and Risks in Modern Hematology 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Can Oligonucleotide Infusions Really Fix Lyme, Cancer, and Other Diseases?

2.

Study: Pre-operative THP leads to pCR in 64% of early-stage HER2+ ER- breast cancer patients

3.

Scientists develop scans that light up aggressive cancer tumors for better treatment

4.

Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth

5.

NIH research cuts leave cancer patient facing hard choice

1.

Uncovering the Hidden Picture: Using Ultrasound to Diagnose Breast Cancer

2.

Comprehensive Updates in Hematology and Quality Improvement

3.

Everything You Need to Know About HTLV: A Comprehensive Guide 

4.

Unlocking the Potential of Talquetamab: A Revolutionary Approach to Cancer Treatment

5.

The Miracle of Tenecteplase: How This Drug Is Saving Lives

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

2.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V

3.

Navigating the Complexities of Ph Negative ALL - Part V

4.

A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

5.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot